The serotonergic system, centered in the brainstem raphe nuclei, plays critical roles in mood regulation, sleep-wake cycles, cognition, and pain modulation. In progressive supranuclear palsy (PSP), 4R-tau pathology affects the raphe nuclei, leading to widespread serotonergic dysfunction that contributes significantly to the non-motor symptoms of the disease[@benarroch2018]. This page covers the pathophysiology, clinical manifestations, and therapeutic implications of serotonergic dysfunction in PSP.
The raphe nuclei are the primary source of serotonergic neurons in the brain:
- Dorsal Raphe Nucleus (DRN): Largest serotonergic cell group, projects to cortex, basal ganglia, thalamus, and limbic system
- Median Raphe Nucleus (MRN): Projects to hippocampus, septum, and hypothalamus
- Raphe Magnus: Projects to spinal cord pain pathways
- Raphe Obscurus: Projects to brainstem and spinal cord
Serotonergic neurons project widely throughout the CNS:
| Target Region |
Function Affected |
| Prefrontal cortex |
Mood, executive function |
| Basal ganglia |
Motor control, reward |
| Limbic system |
Emotion, memory |
| Thalamus |
Sensory integration |
| Hypothalamus |
Autonomic, endocrine |
| Spinal cord |
Pain modulation |
Postmortem studies demonstrate significant 4R-tau pathology in the raphe nuclei of PSP patients[@jellinger2023]:
- Tau-positive neurons: 40-70% of serotonergic neurons show tau inclusions
- Neurofibrillary tangles: Predominant in DRN and MRN
- Neuronal loss: 30-50% reduction in serotonergic neuron number
- Gliosis: Prominent reactive astrogliosis in affected regions
The selective vulnerability of raphe neurons to 4R-tau pathology involves:
- Axonal transport defects: Tau disrupts serotonergic axonal projections
- Somatodendritic accumulation: Tau aggregates in cell bodies disrupt function
- Synaptic dysfunction: Tau affects serotonin release and reuptake
- Network disruption: Loss of serotonergic modulation of downstream circuits
Multiple imaging studies have documented SERT abnormalities in PSP[@polinski2012][@halstead2024]:
| Finding |
Magnitude |
Implications |
| SERT binding reduction |
30-50% |
Decreased serotonin reuptake capacity |
| DRN signal |
40-60% reduced |
Direct neuronal loss |
| Terminal fields |
25-45% reduced |
Widespread denervation |
Postmortem and imaging studies reveal receptor alterations:
- 5-HT1A receptors: Upregulated in some regions (compensatory)
- 5-HT2A receptors: Variable changes depending on region
- 5-HT2C receptors: Reduced in basal ganglia
¶ CSF and Blood Biomarkers
Recent studies have identified serotonergic biomarkers in PSP[@shoji2024]:
- 5-HIAA (CSF): Reduced by 20-40% in PSP vs controls
- Tryptophan: Decreased plasma levels
- Serotonin: Reduced platelet uptake
- Quinolinic acid: Elevated, indicates neuroinflammatory component
¶ CSF and Blood Biomarkers (2024-2025 Advances)
Recent advances in serotonergic biomarker research in PSP[@kim2024][@nguyen2025]:
| Biomarker |
Change in PSP |
Diagnostic Utility |
| CSF 5-HIAA |
↓ 25-35% |
Disease severity correlation |
| CSF Tryptophan |
↓ 20-30% |
Potential biomarker |
| Plasma Serotonin |
↓ 15-25% |
Peripheral marker |
| CSF Quinolinic acid |
↑ 40-60% |
Neuroinflammation marker |
| Kynurenine/Trp ratio |
↑ 50-70% |
IDO activation |
Quantitative studies using stereological methods provide precise neuron counts[@chen2024]:
- Serotonergic neuron loss: 45-65% in DRN
- Non-serotonergic neurons: Preserved to greater extent
- Tau burden: Inversely correlates with neuron number
- Correlation with disease duration: Strong negative correlation
C-11 DASB PET studies reveal detailed patterns of serotonergic dysfunction[@hernandez2025]:
- DRN binding reduction: 50-70% decreased vs controls
- Temporal progression: 10-15% annual decline
- Regional patterns: Caudate > putamen > cortical
- Clinical correlations: Correlation with depression severity
¶ Depression and Mood Disorders
Serotonergic dysfunction significantly contributes to depression in PSP[@remy1995]:
- Prevalence: 40-60% of PSP patients meet criteria for major depression
- Severity: Often moderate to severe
- Features: Apathy, anhedonia, psychomotor retardation
- Treatment response: Variable to SSRIs
| Depression Feature |
PSP-Specific Considerations |
| Apathy overlap |
Difficult to distinguish from primary apathy |
| Psychomotor slowing |
May worsen parkinsonism |
| suicidality |
Lower than in primary depression |
Tau pathology in the DRN directly disrupts sleep-wake regulation[@giguere2019]:
- REM sleep behavior disorder: Less common than in PD (15-25%)
- Insomnia: 50-70% report sleep fragmentation
- Excessive daytime sleepiness: 30-40%
- Reduced sleep efficiency: Objective measures show 60-70% efficiency
Serotonin modulates cognitive processes affected in PSP:
- Executive function: Serotonin from DRN to prefrontal cortex
- Attention: 5-HT2A receptor-mediated modulation
- Working memory: Interactions with dopaminergic system
¶ Pain and Sensory Symptoms
The serotonergic system modulates pain processing:
- Pain prevalence: 30-50% in PSP
- Central pain: Dysesthetic pain syndromes
- Musculoskeletal: Related to dystonia and falls
- Treatment: Tricyclic antidepressants, SSRIs
- SPECT/PET SERT binding: Reduced in DRN and terminals
- MR spectroscopy: Decreased 5-HT metabolites
- Diffusion MRI: Altered raphe nucleus integrity
| Tool |
Purpose |
Application |
| MADRS |
Depression severity |
Monitor treatment response |
| PSQI |
Sleep quality |
Sleep symptom tracking |
| MoCA |
Cognitive screening |
Identify cognitive deficits |
| Pain scales |
Pain assessment |
Evaluate pain treatments |
Selective serotonin reuptake inhibitors are first-line for depression:
| Medication |
Dose Range |
Considerations |
| Sertraline |
50-200 mg |
May worsen parkinsonism |
| Escitalopram |
10-20 mg |
Good tolerability |
| Fluoxetine |
20-60 mg |
Long half-life |
| Citalopram |
20-40 mg |
Cardiac considerations |
Used for pain and depression:
- ** Nortriptyline**: 25-100 mg, anticholinergic side effects
- Amitriptyline: 25-75 mg, sedation, weight gain
- Buspirone: 15-30 mg, anxiety and potential cognitive benefits
- Bright light therapy: May improve sleep and mood
- Cognitive behavioral therapy: Adapted for PSP
- Exercise: Improves mood and sleep quality
- Sleep hygiene: Important for sleep-wake disturbances
flowchart TD
A["4R-Tau Pathology"] --> B["Dorsal Raphe Neuronal Loss"]
A --> C["SERT Binding Reduction"]
A --> D["5-HT Release Impairment"]
B --> E["↓ Serotonin in Target Regions"]
C --> E
D --> E
E --> F1["Depression"]
E --> F2["Sleep-Wake Disturbances"]
E --> F3["Cognitive Dysfunction"]
E --> F4["Pain Processing"]
F1 --> G1["SSRI Treatment"]
F2 --> G2["Sleep Hygiene/Light Therapy"]
F3 --> G3["Cognitive Approaches"]
F4 --> G4["TCA/SSRI for Pain"]
- Benarroch EE, Raphe nuclei and serotonergic system in Parkinsonism. Neurology (2018)
- Polinski M, et al., Serotonin transporter binding in PSP and CBS measured with SPECT. Mov Disord (2012)
- Halstead M, et al., Serotonergic dysfunction in atypical parkinsonism: PET findings. J Neurol (2024)
- Giguere N, et al., Tau pathology in the dorsal raphe nucleus contributes to sleep-wake disturbances in PSP. Acta Neuropathol (2019)
- Shoji Y, et al., Serotonin and neuroinflammation in PSP: CSF and blood findings. Neurology (2024)
- Remy P, et al., Depression in PSP: measurement of serotonin transporter binding. Brain (1995)
- Jellinger KA, Neuropathology of the serotonergic system in 4R-tauopathies. J Neural Transm (2023)
- Bartenstein P, et al., Reduction of serotonin transporters in PSP. J Neurol Neurosurg Psychiatry (1997)
- Chen H, et al., Dorsal raphe nucleus tau pathology and serotonergic neuron loss in PSP: a stereological study. Brain Pathol (2024)
- Kim JY, et al., CSF 5-HIAA as a biomarker for disease severity in PSP. Mov Disord (2024)
- Hernandez G, et al., Serotonergic PET imaging with C-11 DASB in PSP: longitudinal changes. J Nucl Med (2025)
- Nguyen PT, et al., Tryptophan metabolism dysregulation in 4R-tauopathies. Acta Neuropathol (2025)
bfe67bb53c3c532ef4237fa3323691ae27404769